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Inhibition of CRM1-Mediated Nucleocytoplasmic
Transport: Triggering Human Melanoma Cell
Apoptosis by Perturbing Multiple Cellular Pathways
Gaurav Pathria1, Christine Wagner1 and Stephan N. Wagner1,2
Development of multiple drug resistance mechanisms in melanomas necessitates the identification of new drug
targets, which when inhibited could impact multiple cellular pathways, thus circumventing potential resistance.
By performing complementary DNA microarray analysis, we identified four key components of the
nucleocytoplasmic transport machinery—CRM1, RAN (RAN-GTPase), RANGAP1, and RANBP1—to be over-
expressed in human melanoma metastases. Chromosome region maintenance 1 (CRM1) inhibition induced a
marked depletion of prosurvival/cytoplasmic extracellular signal–regulated kinase 1/2 (Erk1/2) and p90 ribosomal
S6 kinase1 and elicited persistent Erk-signaling hyperactivation. Consistently, CRM1 inhibition inflicted
extensive apoptosis in melanoma cells while sparing nontransformed melanocytes and primary lung fibroblasts.
Apoptosis required both the intrinsic and extrinsic apoptotic pathways and was associated with a nuclear
entrapment and downregulation of the antiapoptotic CRM1 target protein, Survivin. Apoptosis was preceded by
a G1 cell-cycle arrest, and even though CRM1 inhibition mediated marked p53 and p21 induction in wild-type
p53 melanoma cells, the latter’s silencing or inactivation failed to alleviate apoptosis. Notably, CRM1 inhibition
induced cell line–specific, G1 to S progression–retarding changes in the expression of multiple cell-cycle
regulatory proteins, thus potentially explaining p53 dispensability. We propose CRM1 as a potential therapeutic
target in human melanoma, whose inhibition induces loss of prosurvival/cytoplasmic Erk1/2, mediates
persistent Erk hyperactivation, and initiates a multitude of cell context–dependent molecular events to trigger
G1 arrest followed by massive apoptosis.
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INTRODUCTION
Cancer cells are marred with multiple, highly complex
molecular alterations. Despite an initial response to most
targeted therapies, cancer cells by the virtue of their profound
molecular heterogeneity mount pronounced drug resistance
through the activation of unrepressed prosurvival/prolifera-
tive pathways. For example, although the drugs specifically
targeting constitutively active BRAFV600E in human melano-
ma stirred an enormous initial enthusiasm (Flaherty et al.,
2010), the development of resistance mechanisms (Nazarian
et al., 2010; Villanueva et al., 2010) precludes their long-term
application in most patients. Therefore, there is an imminent
need of identifying new therapeutic targets that could impact
multiple, nonredundant cellular pathways (Drew et al.,
2002), thus circumventing possible resistance mechanisms
(Arbiser and Fisher, 2011).
Pronounced addiction of rapidly proliferating tumors to
key cellular processes ranging from DNA replication to
cellular metabolism has been exploited for an effective
cancer drug design. Nucleocytoplasmic transport, another
key cellular process involved in shuttling proteins and RNA
molecules out of the nuclear compartment, has come to light
as a possible target for cancer therapy (Kau et al., 2004).
Nucleocytoplasmic transport requiring a close interplay of
several proteins is initiated by the conversion of inactive,
guanosine diphosphate–bound Ran to an active guanosine
triphosphate–bound form, catalyzed by regulator of chromo-
some condensation 1 (Steggerda and Paschal, 2000). Ran
activation is followed by the formation of a ternary complex
between RanGTP, chromosome region maintenance 1
(CRM1), and the nuclear export cargo (Kuersten et al.,
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2001). CRM1, also known as Exportin 1, is a member of the
karyopherin-b family of receptor proteins and has a central
role in nuclear export of the proteins harboring a leucine-rich
nuclear export sequence (NES; Wolff et al., 1997). The
ternary complex once exported out of the nucleus is
disassembled by a concerted action of RanBP1 and RanGAP1
(Kuersten et al., 2001).
Enhanced cytoplasmic accumulation of several tumor
suppressor proteins has recently been suggested as an
additional mechanism acquired by cancer cells to attain
enhanced proliferative potential (Turner and Sullivan, 2008).
CRM1 function as a central nuclear export protein, its
overexpression in cancer cells in comparison with their
normal counterparts (Huang et al., 2009; van der Watt et al.,
2009), and a positive correlation of its expression with poor
disease prognosis (Noske et al., 2008; Shen et al., 2009) posit
it as an attractive cancer drug target. CRM1-mediated nuclear
export of multiple proliferation-associated proteins including
Rb (Jiao et al., 2008), p53, p21, p27, FOXO-3A transcription
factors (Turner and Sullivan, 2008), mitogen-activated protein
kinase/extracellular signal–regulated kinase (Mek; Fukuda
et al., 1996), extracellular signal–regulated kinase (Erk; Adachi
et al., 2000), and Survivin (Rodriguez et al., 2002) further
suggest its potential deregulation in tumors and targetability.
Tumor suppressor p53 carries a functional NES (Stommel
et al., 1999). Leptomycin B (LMB), a highly specific CRM1
inhibitor, blocks p53 nuclear export and subsequent degra-
dation, thus elevating its levels primarily in the nucleus
(Freedman and Levine, 1998). This has been suggested as the
mechanism for CRM1 inhibition–mediated tumor cell cyto-
toxicity (Lecane et al., 2003; Smart et al., 1999). Other than
p53, the mechanistic understanding of CRM1 inhibition–
induced apoptosis is incomplete.
A potential deregulation of nucleocytoplasmic transport
with a consequent cellular mislocalization of key prolifera-
tion-associated molecules has never been investigated in
melanoma. Furthermore, the prospect of this key cellular
pathway as a possible therapeutic target in melanoma has
remained unexplored. Herein, we suggest a critical require-
ment of CRM1-mediated nuclear export for aberrant cyto-
plasmic/prosurvival Erk activity. By using multiple melanoma
cell lines, we demonstrate that CRM1 inhibition while
reversing cytoplasmic Erk localization and inducing persis-
tent Erk signaling hyperactivity induces multiple cell con-
text–dependent molecular alterations to effect G1 arrest
followed by melanoma cell apoptosis.
RESULTS
CRM1, RAN (RAN-GTPase), RANBP1, and RANGAP1 are
overexpressed in metastatic melanoma
To test the hypothesis that cancer cells upregulate the rate of
nucleocytoplasmic transport to keep up with enhanced
proliferation rates, we analyzed our previously generated
gene expression data from human tissue samples of melano-
cytic nevi, primary melanomas, melanoma metastases, and
human melanoma cell lines (Jalili et al., 2011). CRM1, RAN
(RAN-GTPase), RANBP1, and RANGAP1, all known to have
a crucial role in nuclear export process, were significantly
overexpressed in metastatic melanoma samples and melano-
ma cell lines in comparison with primary melanomas and
melanocytic nevi (Figure 1). Human melanoma cell lines also
exhibited higher CRM1 protein expression in comparison
with immortalized/nontransformed human melanocytes
(p0-Mel; Supplementary Figure S1 online).
Melanoma cells exhibit predominant cytoplasmic Erk
localization, which is reversed by CRM1 inhibition
Sufficient body of data suggests a tumor survival function for
cytoplasmic Erk (Ajenjo et al., 2004; Hendrickson et al.,
2008). Notably, a decrease in the cytoplasmic but not the
nuclear phospho-Erk (p-Erk) correlated with a favorable
outcome in melanoma patients (Bollag et al., 2010).
Furthermore, Houben et al. (2008) nicely demonstrated a
predominant cytoplasmic localization of active Erk in human
melanoma samples. Although a role of cytoplasmic scaffold
proteins has been suggested (Torii et al., 2004), additional
cellular mechanisms responsible for predominant cyto-
plasmic Erk localization remain elusive. Even though the
Erk2 dimer interface contains a putative NES (Wen et al.,
1995), Adachi et al. (2000) revealed dependence on NES-
harboring Mek1 for CRM1-dependent Erk nuclear export. As
we observed the overexpression of key nuclear export
components in metastatic melanomas, we asked whether a
consequently enhanced nuclear export could mediate a
predominant cytoplasmic localization of Erk in melanoma
cells, thus endowing them with survival advantage. We
observed prominent cytoplasmic Erk staining in melanoma
cells (Figure 2a). LMB triggered nuclear entrapment of Mek1
(Supplementary Figure S2 online) and Erk1/2 in a stable
manner (Figure 2a and b). These results strongly suggest a role
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Figure 1. Chromosome region maintenance 1 (CRM1) expression is
significantly upregulated in human metastatic melanoma. Relative mRNA
expression levels (y-axis) of CRM1, RAN (RAN-GTPase), RANBP1, and
RANGAP1 in melanocytic nevi (n¼9), primary human melanoma (n¼31),
human melanoma metastases (n¼ 52), and human melanoma cell lines
(n¼15). ****Pp0.0001, ***Pp0.001, **Pp0.01, *Pp0.05. Error bars
indicate ±SD.
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of hyperactive nuclear export machinery in mediating
predominant cytoplasmic Erk localization in melanoma
cells and advocate a previously unreported approach for
reversing it.
CRM1 inhibition hyperactivates the Erk signaling pathway
Adachi et al. (2000) suggested that Erk nuclear entrapment
could terminate MAPK signaling, as dephosphorylated Erk
entrapped in the nucleus could not recycle back to the
cytoplasm for the next round of phosphorylation/activation.
Prompted by this suggestion, we asked whether the observed
Erk nuclear entrapment (Figure 2) could indeed compromise
Mek–Erk signaling. In line with Erk1/2 nuclear accumulation,
CRM1 inhibition increased the proportion of nuclear p-Erk1/2
(Figure 3a). However, much to our surprise, CRM1 inhibition
mediated hyperphosphorylation (primarily nuclear) of Erk1/2
in eight of the nine melanoma cell lines tested (Figure 3a
and b, and Supplementary Figure S3a online). Induction
of p-Erk1/2 in Hek293 cells suggested a more general
character of this phenomenon (Supplementary Figure S3b
online). Similar Erk hyperphosphorylation upon small
interfering RNA (siRNA)–mediated CRM1 silencing and its
dose-dependent response to LMB supported a CRM1-specific
character (Figure 3c and d). Induced p-Erk1/2 was associated
with hyperphosphorylation of its target p90 ribosomal S6
kinase 1 (p90RSK1; Figure 3b), which could significantly
be suppressed by the Mek inhibitor, U0126 (Figure 3e and
Supplementary Figure S10c online). Interestingly, by perform-
ing protein sequence analysis of p90RSK1, we identified a
highly conserved leucine-rich stretch (aa 174–183), which
was in consensus with the previously established NES
(Henderson and Eleftheriou, 2000; Figure 3f). Consistently,
a sequence analysis using NESbase (la Cour et al., 2003;
http://www.cbs.dtu.dk/services/NetNES/) also projected the
same stretch as a potential NES. Further, CRM1 inhibition
increased nuclear localization of p90RSK1, thus suggesting its
CRM1-mediated nuclear export (Figure 3g). The presence of
this potential NES in p90RSK1 and its nuclear entrapment
along with Erk1/2 upon CRM1 inhibition could explain its
hyperphosphorylation. Furthermore, Erk hyperphosphoryla-
tion was associated with an upregulation of its transcriptional
targets, c-Fos (Marais et al., 1993; Figure 3h) and c-Jun (Leppa
et al., 1998; Supplementary Figure S3c online). In line with
c-Fos and c-Jun induction, we also observed an upregulation
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Figure 2. Chromosome region maintenance 1 (CRM1) inhibition induces cytoplasmic extracellular signal–regulated kinase (Erk) depletion.
(a, left) Immunofluorescent staining for Erk1/2 in the indicated cell lines upon 6 hours of treatment with leptomycin B (LMB; left panel). Nuclear staining with
40,6-diamidino-2-phenylindole (DAPI; middle panel). Overlay of Erk1/2 and nuclear stain (right panel). (a, right) Quantification of Erk1/2 cellular distribution.
Cells were scored for predominant cytoplasmic (C4N), equal cytoplasmic and nuclear (C¼N) or predominant nuclear (CoN) distribution of Erk1/2. More than
80 cells were scored and the distribution was plotted (y-axis) as the percentage of all the cells scored. Error bars indicate ±SD from the representative
experiment performed in duplicate. (b) Immunofluorescence-based time-course analysis of Erk1/2 localization (left panel) in UACC62 cells. Cells were stained
at 6, 18, or 48 hours after leptomycin B (LMB) treatment. Nuclei stained with DAPI (middle panel). Right panel shows the overlay. (SK28—SK-MEL-28).
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of cyclin D1 (Lopez-Bergami et al., 2007; Supplementary
Figure S3d online).
CRM1 inhibition induces melanoma cell apoptosis regardless of
p53 functional status, whereas nontransformed melanocytes
and primary lung fibroblasts exhibit profound resistance
A loss of cytoplasmic/prosurvival Erk (Rosseland et al., 2005;
Figures 2a and 3a) and the known ability of persistently
hyperactivated nuclear Erk signaling (Figure 3) to induce
apoptosis (Cagnol and Chambard, 2010) suggested an
antiproliferative response to CRM1 inhibition. To this end,
we analyzed the effect of LMB-mediated CRM1 inhibition in
genetically heterogeneous human melanoma cell lines
(Supplementary Table S1 online). Cell lines with variable
p53 functional status (Supplementary Table S1 online) were
included to investigate in melanoma cells, a previously
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Figure 3. Chromosome region maintenance 1 (CRM1) inhibition mediates extracellular signal–regulated kinase (Erk)-signaling hyperactivation.
(a, left) Immunofluorescence staining for phospho-Erk1/2 (p-Erk1/2) in the indicated cell lines upon 6 hours of leptomycin B (LMB) treatment. (a, right)
Quantification was performed as discussed in Figure 2a. (b) Western blotting for p-Erk1/2, Erk1/2, phospho-p90RSK1 (p-p90RSK1), and p90RSK1 in the indicated
cell lines treated with LMB for 6 or 18 hours. (c) Western blotting for CRM1, p-Erk1/2, and Erk1/2 in the indicated cell lines upon 72 hours of treatment with
control small interfering RNA (Ctrl-siRNA) and siRNA–CRM1 (si-CRM1#1 or si-CRM1#2). (d, upper panel) UACC62 cells were treated with an increasing dose of
LMB (as indicated) for 6 hours, followed by western blotting for p-Erk1/2 and Erk1/2. (d, lower panel) Densitometric units of p-Erk1/2 normalized with Erk1/2.
(e) UACC62 cells were treated for 6 hours as indicated, followed by assessment of phospho-p90RSK1 and p90RSK1 levels by western blotting. (f) Amino-acid
sequence alignment of a potential nuclear export sequence (NES) in p90RSK1 (aa 174–183) with established NES from the indicated proteins. (g, top) Upper
panel, immunofluorescence-based analysis of p90RSK1 distribution in UACC62 cells upon 6 hours of LMB treatment. Middle panel, nuclear staining with
40,6-diamidino-2-phenylindole (DAPI). Lower panel, overlay of p90RSK1 and the nuclear stain. (g, bottom) Quantification of p90RSK1 cellular distribution.
(h) Indicated cell lines were treated with LMB for 18 hours, followed by western blotting for c-Fos. (SK5—SK-MEL-5).
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demonstrated (in other cellular systems) p53 requirement for
LMB-mediated apoptosis (Smart et al., 1999; Lecane et al.,
2003). All the tested cell lines exhibited a significant viability
loss at LMB concentration as low as 2.0 nM (Figure 4a).
Further, siRNA-mediated CRM1 silencing inflicted a severe
proliferative defect in human melanoma cells (Figure 4b
and Supplementary Figure S4 online). Increased sub-G1 cell
fraction (Figure 4c), AnnexinV/AnnexinVþ propidium iodide
(PI) positivity (Figure 4d), and caspase-3 cleavage (Figure 4e)
upon LMB treatment along with pan-caspase inhibitor
(Z-VAD-FMK)–mediated rescue of cell death (Figure 4f)
altogether established apoptosis as the mechanism of CRM1
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Figure 4. Chromosome region maintenance 1 (CRM1) inhibition suppresses melanoma cell viability through apoptotic induction. (a) Indicated cell lines
were left untreated or treated as shown (x-axis). Cell viability estimated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is
expressed as absorbance at 492nm (y-axis). Error bars indicate ±SD from the representative experiment performed in triplicate. (b, left) Western blotting
for CRM1 in the indicated cell lines 72 hours after control small interfering RNA (Ctrl-siRNA) or si-CRM1#1 treatment. (b, right) Increase in absolute cell numbers (y-
axis) was determined by subtracting cell number at the time of seeding from the cell number at 96 hours post si-CRM1#1 transfection. Error bars indicate±SD from
the representative experiment performed in triplicate. (c) Cell-cycle analysis of UACC62 and M14 cells 24 hours post leptomycin B (LMB) treatment. (d) UACC62
and M14 cells were treated with LMB for 48 hours, followed by AnnexinV/propidium iodide (PI) staining. Numbers on the top right quadrant indicate the proportion
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cleaved fragments) and uncleaved-Bid were detected by western blotting. (j) UACC62 and M14 cells were treated with LMB for 32 hours followed by western
blotting for Bcl-2. (k) AnnexinV/PI staining in UACC62, SK28, and M14 cells upon the indicated set of treatments for 48 hours. Z-IETD-FMK (20mM), caspase-8
inhibitor; Z-VAD-FMK (40mM), pan-caspase inhibitor; DMSO, solvent for caspase inhibitors.
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inhibition–mediated viability loss. Apoptotic induction was
seen in all the tested melanoma cell lines (Supplementary
Figure S5a online), whereas immortalized/nontransformed
human melanocytes (p0Mel-BRAFV600E; Garraway et al.,
2005) and human primary lung fibroblasts (IMR90) demon-
strated a profound resistance to LMB-induced apoptosis
(Figure 4g). A long-term clonogenic assay further showed
profound resistance of IMR90 cells to CRM1 inhibition in
contrast to human M14 melanoma cells (Supplementary
Figure S6 online). Quite remarkably, an increase in LMB
concentration from 4nM to 40 nM failed to increase the
magnitude of apoptosis, underscoring the high specificity and
efficacy of the drug (Supplementary Figure S5b online) at
extremely low concentrations.
Both extrinsic and intrinsic apoptotic pathways are involved in
CRM1 inhibition–mediated melanoma cell apoptosis
Although past studies have documented apoptotic induction
in cancer cells upon CRM1 inhibition (Turner and Sullivan,
2008), the relative contribution of extrinsic/intrinsic path-
ways has never been investigated. Cleavage of caspase-9
(Figure 4h) indicated the activation of the intrinsic pathway,
whereas caspase-8 and Bid cleavage upon CRM1 inhibition
suggested an involvement of the extrinsic apoptotic pathway
(Figure 4i). Interestingly, CRM1 inhibition did not suppress
anti-apoptotic Bcl-2 levels at earlier time points (Supple-
mentary Figure S5c online), whereas its downregulation
was observed at a later time point (Figure 4j), suggesting its
involvement in late apoptosis. To conclusively evaluate the
involvement of either apoptotic branch, cells were cotreated
with caspase-8 inhibitor (Z-IETD-FMK) and LMB. Interest-
ingly, cells exhibited partial apoptotic rescue upon cotreat-
ment with the caspase-8 inhibitor (Figure 4k). In contrast, a
pan-caspase inhibitor (Z-VAD-FMK) yielded complete apop-
totic rescue in all the cell lines tested (Figure 4k), thus arguing
for an involvement of both the extrinsic and intrinsic
pathways in CRM1 inhibition–induced apoptosis.
Erk hyperphosphorylation has a role in CRM1
inhibition–induced early apoptosis
To test the causal relationship between hyperactivated Erk
and melanoma cell apoptosis upon CRM1 inhibition, we
pretreated melanoma cells with U0126, followed by treat-
ment with LMB for 24 or 48 hours. Interestingly, a suppres-
sion of p-Erk partially rescued early (24 hours) apoptosis
while conferring no effect on the late apoptosis (48 hours;
Supplementary Figure S7 online).
CRM1 inhibition–induced apoptosis is associated with Survivin
nuclear entrapment and downregulation
Survivin is an established prosurvival/anti-apoptotic factor in
human melanoma (Grossman et al., 2001), and is exported
from the nucleus in a CRM1-dependent manner (Rodriguez
et al., 2002). The previously demonstrated ability of lone
Survivin silencing to induce apoptosis in melanoma cells
(Grossman et al., 1999) underscores the prosurvival function
of this inhibitor of apoptosis family member. Predominant
cytoplasmic localization of Survivin maintained by the
presence of a functional NES is required for its antiapoptotic
activity (Knauer et al., 2007), and a study by Chan et al. (2010)
showed that Survivin’s leakage into the nucleus is followed by
its ubiquitinylation and proteasomal degradation. Given
Survivin’s overexpression in metastatic melanoma samples
and melanoma cell lines (Figure 5a) and the fact that CRM1
inhibition could induce Survivin’s nuclear entrapment and
subsequent degradation, we asked whether this mechanism is
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intact in melanoma cells and could therefore contribute
toward melanoma cell apoptosis upon CRM1 inhibition. Loss
of CRM1 functionality mediated a significant nuclear accu-
mulation of Survivin (Figure 5b), followed by a suppression of
its protein levels (Figure 5c and d).
G1 cell cycle arrest precedes CRM1 inhibition–induced
apoptosis
To unravel immediate upstream events preceding CRM1
inhibition–induced apoptosis and understand the possible
role of p53, we studied the cell-cycle distribution of wild-type
(wt; SK-MEL-5) and mutant p53 (M14 and MeWo) human
melanoma cell lines upon CRM1 inhibition. As shown in
Figure 6a, CRM1 inhibition retarded the cell-cycle progres-
sion at G1 phase with an associated Rb hypophosphorylation,
irrespective of the p53 functional status.
CRM1 inhibition induces p53 exclusively in wt p53
melanoma cells and requires a functional p53
Our results (Figures 4 and 6a, and Supplementary Figure S5
online) suggested p53 dispensability for CRM1 inhibition–
induced G1 arrest and apoptosis in melanoma cells harboring
a nonfunctional mutant p53, but could not clarify its require-
ment in wt p53 melanoma cells. To this end, we analyzed the
effect of LMB on p53 levels in a panel of melanoma cell lines
with differing p53 mutational status (Supplementary Table S1
online). Interestingly, CRM1 inhibition mediated significant
p53 induction exclusively in the cells harboring both wt p53
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alleles (Figure 6b). Consistently, we also observed elevated
expression of p53 transcriptional targets, p21 and Mdm2
(Figure 6b). p53 immunostaining indicated the nuclear
character of induced p53 (Figure 6c). These results further
substantiated p53 involvement in CRM1 inhibition–mediated
apoptosis and cell-cycle arrest exclusively in the wt p53 cells.
Mdm2-mediated p53 ubiquitinylation exposes the latter’s
NES, promoting its interaction with CRM1 with a consequent
enhancement of its nuclear export and cytoplasmic degrada-
tion (Marine and Lozano, 2010). Observed p53 induction
upon CRM1 inhibition is likely mediated by the suppression
of this pathway. Melanoma cell lines carrying even a single
mutant p53 allele exhibited extremely low levels of Mdm2
likely because of the dominant-negative character of p53
mutation and thus a loss of Mdm2 transcriptional upregula-
tion (Figure 6b). These low Mdm2 levels could consequently
account for high endogenous/nuclear p53 levels in these cells
(Figure 6b and c). The arguments above could also explain an
absence of p53 induction in the mutant p53 cell lines upon
CRM1 inhibition. To further strengthen the hypothesis that an
intact p53 transcriptional activity is indeed required for LMB-
mediated p53 induction, we suppressed the transcriptional
activity of wt p53 in UACC62 cells, using the p53 inhibitor
Pifithrin-a. Confirming our hypothesis, Pifithrin-a markedly
subdued LMB-mediated p53 induction upon a suppression of
its transcriptional activity, as demonstrated by suppression of
Mdm2 (Figure 6d).
p53 is dispensable for CRM1 inhibition–induced apoptosis
To conclusively evaluate p53 involvement in LMB-induced
apoptosis, particularly in the melanoma cells harboring wt
p53 alleles and capable of upregulating p53 and p21
levels, we adopted two approaches: (1) siRNA-mediated
p53 silencing and (2) Pifithrin-a-mediated suppression of
p53 transcriptional activity. Quite remarkably, neither of
these approaches could relieve CRM1 inhibition–induced
apoptosis (Figure 6e and f, and Supplementary Figure S8
online). Although combined treatment with LMB and
si-p53 failed to completely suppress p53 protein levels in
UACC62 cells (Figure 6e), it successfully overcame the
significant induction of p53 seen upon lone LMB treatment
(Figure 6b). Utilization of Pifithrin-a bypassed this problem
by significantly suppressing p53 transcriptional activity
(Figure 6d).
CRM1 inhibition–induced Rb hypophosphorylation and G1
arrest is associated with a change in the expression of multiple
cell-cycle regulatory proteins
To understand an apparent dispensability for p53 and gain
insights into the molecular events transcending into Rb
hypophosphorylation, followed by a G1 arrest, we asked
whether CRM1 inhibition could affect G1 arrest by modulat-
ing the expression of additional cell cycle regulatory
molecules. As summarized in Figure 6g (raw data is shown
in Figure 6b and Supplementary Figures S3d and S9a–e
online), upon CRM1 inhibition each cell line exhibited at
least two molecular events (shown in red) known to suppress
Rb phosphorylation and induce G1 arrest.
DISCUSSION
Transmission of prosurvival signals by cytoplasmic Erk has
previously been demonstrated. For example, cytoplasmic
p-Erk confers survival in hepatocytes exposed to hydrogen
peroxide (Rosseland et al., 2005). A study by Ajenjo et al.
(2004) revealed cytoplasmically restricted Erk2 to counter
serum starvation–induced apoptogenic signal. Our results and
a previous report demonstrating predominant cytoplasmic
localization of active Erk1/2 in melanoma tissue samples and
cell lines (Houben et al., 2008) could explain its protective
(antiapoptotic) role in response to extracellular cues, includ-
ing growth factor deprivation. Consistently, a recent report by
Bollag et al. (2010) demonstrated a better tumor response to
the BRAF inhibitor PLX4032 in the samples showing a
decrease in cytoplasmic p-Erk in comparison with those
showing a decrease in nuclear p-Erk, thus further under-
scoring the importance of cytoplasmic p-Erk in human mela-
noma prosurvival signaling. Overexpression of key nuclear
export components and a marked loss of cytoplasmic Erk
gradient upon CRM1 inhibition revealed in the current study
advocates a likely involvement of CRM1-mediated nuclear
export in achieving predominant cytoplasmic Erk locali-
zation. Observed loss of prosurvival/cytoplasmic Erk upon
CRM1 inhibition (current study) and a potential dephos-
phorylation/inactivation of B60 cytoplasmic Erk targets
(Yoon and Seger, 2006) stands as a possible trigger for
CRM1 inhibition–induced apoptosis. Furthermore, cyto-
plasmic p90RSK-mediated regulation of cellular growth
and proliferation (Hauge and Frodin, 2006) and our revela-
tion of a previously unreported potential NES in p90RSK1 and
its nuclear entrapment upon CRM1 inhibition proposes an addi-
tional mechanism for compromised melanoma cell viability.
To the best of our knowledge, persistent Erk nuclear
entrapment, its hyperphosphorylation, and an associated
increase in its kinase activity (as demonstrated by increased
p90RSK1 phosphorylation) upon CRM1 inhibition have
previously never been reported. Our results further reveal
the contribution of these events toward CRM1 inhibition–
induced apoptosis and are supported by earlier studies
demonstrating a correlation between sustained nuclear Erk
activity and apoptosis (Cagnol and Chambard, 2010).
Hyperactive Erk induces apoptosis through diverse mecha-
nisms including: (1) the activation of caspase-8 signaling
via upregulation of tumor necrosis factor-a, FasL, or death
receptors such as DR4, DR5, and Fas, and (2) the induction of
mitochondrial cytochrome C release by an upregulation
of proapoptotic Bax, PUMA, and Bak and a downregulation
of antiapoptotic members Bcl-2 and Bcl-XL (Cagnol and
Chambard, 2010). Notably, the known ability of active Erk
to induce caspase-8 cleavage followed by proteolytic
cleavage of Bid to induce mitochondrial cytochrome C
release (Li et al., 2007) and our results demonstrating similar
biochemical changes reinforce the role of hyperactive Erk in
mediating CRM1 inhibition–induced apoptosis.
Interestingly, p-Mek induction did not correlate with
Erk hyperactivation (Supplementary Figure S10a online).
Even though CRM1 inhibition induced Akt activation, the
involvement of Mek-independent pathways (Aksamitiene
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et al., 2010) in p-Erk induction was excluded by a complete
loss of p-Erk levels upon combined treatment with LMB
and U0126 (Supplementary Figure S10b and c online). The
known ability of reactive oxygen species to suppress the
activity of nuclear dual-specificity phosphatases (Cagnol and
Chambard, 2010) and a nuclear character of induced p-Erk
(current study) suggests a possible involvement of this
pathway and would be a subject of further investigation.
Our results revealing nuclear entrapment and downregu-
lation of anti-apoptotic Survivin unveils a unique property of
CRM1-targeted inhibition to overcome established resis-
tance mechanisms in melanoma cells. Interestingly, we also
observed a downregulation of ML-IAP (melanoma inhibitor of
apoptosis; Vucic et al., 2000) in several melanoma cell lines
(data not shown).
While mechanistically accounting for a huge p53 induc-
tion exclusively in the wt p53 melanoma cells, our data
demonstrate that in contrast to several previous reports (Smart
et al., 1999; Lecane et al., 2003) CRM1 inhibition–induced
G1 arrest and apoptosis are not critically dependent on p53.
This observation, coupled to the fact that p53 functionality is
compromised in a significant proportion of melanomas (Yang
et al., 2005), further corroborates the candidature of CRM1 as
an attractive therapeutic target. Although our data mechan-
istically account for Rb hypophosphorylation and a subse-
quent G1 arrest by associated changes in the expression of
various cell-cycle regulatory proteins, we currently lack an
understanding of these complex molecular events. It would
be reasonable to expect even more complex upstream events
eventually transpiring into these changes.
Loss of prosurvival/cytoplasmic Erk/p90RSK1, persistent
nuclear Erk hyperactivity, nuclear entrapment of Survivin,
followed by its downregulation and altered expression of
multiple cell-cycle regulators underscore a simultaneous
involvement of multiple pathways in mediating CRM1
inhibition–induced melanoma cell apoptosis. The ability of a
concomitant Erk activity suppression to partially rescue only
the CRM1 inhibition–induced early melanoma cell apoptosis
and a failure of p53 suppression to confer any effect on CRM1
inhibition–induced apoptosis further supports this model. This
model compares to a road network comprising multiple small
roads impinging on to a major highway. During traffic jam on
one of the small roads, the driver could still choose another
small road to reach the highway. Translating to a cellular
context, multiple proapoptotic signals induced upon CRM1
inhibition are small roads, apoptosis is the major highway,
and the blockade of one of the proapoptotic signals (e.g.,
blocking the p53 pathway) is a jam. Consistently, Tsuchiya
et al. (2006) showed that although PP2A inhibition could
reverse LMB-mediated cyclin D1 downregulation it failed to
rescue the ensuing G1 arrest.
Although a recent surge in the development of additional
CRM1 inhibitors (Mutka et al., 2009; Sakakibara et al., 2011)
underscores its attractiveness as a potential cancer therapy
target, it has also necessitated the elucidation of molecules
and pathways mediating the cytotoxic effects of these
inhibitors. Results in this study demonstrating contextual
involvement of multiple cellular pathways should provide a
mechanistic groundwork for the development and applica-
tion of new CRM1 inhibitors for treatment of melanoma and
other malignancies exhibiting profound CRM1 dependence.
MATERIALS AND METHODS
Cell culture and reagents
Cell lines were cultured in RPMI, supplemented with 10% fetal calf
serum. Immortalized/nontransformed human melanocytes, p0mel/
hTERT/CDK4(R24C)/p53DD, referred to as p0-Mel and p0-Mel-harbor-
ing BRAF(V600E) (Garraway et al., 2005), referred to as p0Mel-
BRAFV600E, were a generous gift from Hans Widlund (Brigham and
Women’s Hospital, Boston, MA). LMB (Sigma-Aldrich, Vienna,
Austria), U0126 (Selleck Chemicals LLC, Houston, TX), Pifithrin-a
(Enzo Life Sciences, Ann Arbor, MI), AnnexinV-FITC (BD Biosciences,
Schwechat, Austria), and PI (Sigma-Aldrich) were used in this study.
LMB was used at a concentration of 4nM unless otherwise specified.
Methanol (70%) was used as a solvent control (Mock ()) for all
experiments involving LMB.
Antibodies
Anti-CRM1 (H-300), anti-Bcl-2, anti-Mek (C-18), anti-p-Mek1/2
(Ser218/Ser222), anti-p53 (DO-1) anti-p27 (N-20), anti-p21
(H-164), anti-p16 (F-12), anti-p18 (N-20), anti-Cdk2 (D12), anti-
Cdk4 (C-22), anti-Cdk6 (B-10), and anti-RSK-1 (C-21) were obtained
from Santa Cruz Biotechnology Santa Cruz, CA; anti-phospho-Akt
(Ser473), anti-c-Jun (60A8), anti-c-Fos (9F6), anti-caspase-8, anti-
Bid, anti-cleaved caspase-3, anti-cleaved caspase-9, anti-phospho-
Erk1/2 (Thr202/Tyr204), anti-Erk1/2, anti-phospho-p90RSK1
(Thr359/Ser363), and anti-phospho-Rb (Ser780) were obtained from
Cell Signaling Technology, Danvers, MA; anti-a-Tubulin antibody
was from Calbiochem, Merck, Darmstadt, Germany; and anti-
human Survivin from R&D Systems, Darmstadt, Germany.
Gene expression profiling
Tissue sampling and gene expression profiling have previously been
performed using the Affymetrix U133A microarray platform (Jalili
et al., 2011) as described earlier (Xu et al., 2008). The data have
been deposited in the National Center for Biotechnology Information
GEO (Clark et al., 2000) and are accessible through GEO Series
accession no. GSE8401.
MTT assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was performed as described previously (Jalili et al., 2011).
RNA interference
siRNA transfections using CRM1-siRNA (s14937 (#1) and
s14939 (#2); Ambion, Austin, TX), p53-siRNA (h2; Santa Cruz
Biotechnology), and negative control siRNA (AM4637; Ambion)
were performed using Lipofectamine 2000 transfection reagent
(Invitrogen, Vienna, Austria) as per the manufacturer’s instructions.
Cell-cycle analysis
Cell-cycle analysis was performed as previously described (Jalili
et al., 2011). Hypodiploid (necrotic/apoptotic; sub-G1 phase),
diploid (G1/G0 phase), hyperdiploid (S phase), and tetraploid
(G2/M) cell populations were quantified using the CellQuest
software (BD Biosciences, Heidelberg, Germany).
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AnnexinV/PI and caspase inhibition assays
AnnexinV/PI-based apoptosis detection was performed as previously
described (Jalili et al., 2011). Early-apoptotic cells (AnnexinV
positive), late-apoptotic cells (AnnexinV and PI positive), and
viable cells (AnnexinV and PI negative) were detected using
FACSCalibur (Heidelberg, Germany) and subsequent analysis was
performed using the CellQuest software (BD Biosciences). For
evaluating the effects of caspase-8 inhibitor Z-IETD-FMK (20 mM;
BD Biosciences) and pan-caspase inhibitor Z-VAD-FMK (40mM; BD
Biosciences), melanoma cells were pretreated with either of the
two caspase inhibitors for 2 hours, followed by LMB treatment. At 48
hours post LMB treatment, cells were analyzed for apoptosis, as
described above.
Western blotting
Western blotting was performed as previously described (Jalili et al.,
2011). a-Tubulin or GAPDH staining was used as a control for equal
sample loading.
Immunofluorescence
Cells seeded onto a 96-well Imaging plate FC (PAA Laboratories,
Pasching, Austria) were briefly washed with phosphate-buffered
saline (PBS; Invitrogen), fixed with 4% paraformaldehyde, and
permeabilized using 90% methanol. Following three washes with
PBS, cells were blocked for 30 minutes at room temperature, using
20% goat or rabbit serum (DakoCytomation, Glostrup, Denmark).
Primary antibody treatment was performed overnight at 4 1C. After
three washes with PBS, cells were incubated with Alexa-Fluor
488–labeled secondary antibody for 2 hours. Cells were subse-
quently washed and treated with the nuclear dye, 40,6-diamidino-2-
phenylindole, dihydrochloride (Molecular Probes, Eugene, OR), as
per the manufacturer’s instructions. Images were acquired and
analyzed using the Zen 2008 (version 5.0) software on an Axiovert
200M inverted microscope (Zeiss, Oberkochen, Germany).
Statistical analysis
Graphpad prism software 5.0 (Graphpad, La Jolla, CA; http://
www.graphpad.com) was used to perform statistical analysis by
performing unpaired t-test.
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